Limits...
Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy.

Rush RB, Rush SW - J Ophthalmol (2015)

Bottom Line: Results.Conclusions.Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy.

View Article: PubMed Central - PubMed

Affiliation: Southwest Retina Specialists, 7411 Wallace Boulevard, Amarillo, TX 79106, USA ; Panhandle Eye Group, 7400 Fleming Avenue, Amarillo, TX 79106, USA ; Texas Tech University Health Science Center, 1400 S. Coulter, Amarillo, TX 79106, USA.

ABSTRACT
Purpose. To examine the clinical implications of change in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography in subjects with idiopathic CNV undergoing bevacizumab therapy. Methods. The charts of subjects with an idiopathic CNV treated by a modified PRN regimen with intravitreal bevacizumab over a 12-month period were retrospectively reviewed. Results. There were 34 subjects included in the analysis. Baseline CNV sizes of less than 1.0 mm(2) on ICG angiography correlated with complete CNV resolution (P = 0.0404), fewer injections delivered (P = 0.0002), and better Snellen visual acuity (P = 0.0098) at 12 months. Subjects that experienced a 33% or more reduction in CNV size on ICG angiography at 2 months had complete CNV resolution (P = 0.0047) and fewer injections (P < 0.0001) at 12 months compared to subjects that did not experience a 33% or more reduction in CNV size on ICG angiography at 2 months. Conclusions. Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy.

No MeSH data available.


Related in: MedlinePlus

The fluorescein angiography (a) and indocyanine green angiography (b) images of the same subject presented in Figures 1 and 2 two months after two consecutive monthly bevacizumab injections were given. The choroidal neovascularization has decreased 45.3% ((0.86 − 0.47)/0.86) from its baseline value on indocyanine green angiography. The Snellen visual acuity improved to 20/30.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4465762&req=5

fig3: The fluorescein angiography (a) and indocyanine green angiography (b) images of the same subject presented in Figures 1 and 2 two months after two consecutive monthly bevacizumab injections were given. The choroidal neovascularization has decreased 45.3% ((0.86 − 0.47)/0.86) from its baseline value on indocyanine green angiography. The Snellen visual acuity improved to 20/30.

Mentions: The optical coherence tomography image of the same subject presented in Figures 1–3 two months after two consecutive monthly bevacizumab injections were given. Notice the resolution of most of the retinal fluid and the choroidal neovascularization diminishment within the subretinal space.


Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy.

Rush RB, Rush SW - J Ophthalmol (2015)

The fluorescein angiography (a) and indocyanine green angiography (b) images of the same subject presented in Figures 1 and 2 two months after two consecutive monthly bevacizumab injections were given. The choroidal neovascularization has decreased 45.3% ((0.86 − 0.47)/0.86) from its baseline value on indocyanine green angiography. The Snellen visual acuity improved to 20/30.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4465762&req=5

fig3: The fluorescein angiography (a) and indocyanine green angiography (b) images of the same subject presented in Figures 1 and 2 two months after two consecutive monthly bevacizumab injections were given. The choroidal neovascularization has decreased 45.3% ((0.86 − 0.47)/0.86) from its baseline value on indocyanine green angiography. The Snellen visual acuity improved to 20/30.
Mentions: The optical coherence tomography image of the same subject presented in Figures 1–3 two months after two consecutive monthly bevacizumab injections were given. Notice the resolution of most of the retinal fluid and the choroidal neovascularization diminishment within the subretinal space.

Bottom Line: Results.Conclusions.Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy.

View Article: PubMed Central - PubMed

Affiliation: Southwest Retina Specialists, 7411 Wallace Boulevard, Amarillo, TX 79106, USA ; Panhandle Eye Group, 7400 Fleming Avenue, Amarillo, TX 79106, USA ; Texas Tech University Health Science Center, 1400 S. Coulter, Amarillo, TX 79106, USA.

ABSTRACT
Purpose. To examine the clinical implications of change in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography in subjects with idiopathic CNV undergoing bevacizumab therapy. Methods. The charts of subjects with an idiopathic CNV treated by a modified PRN regimen with intravitreal bevacizumab over a 12-month period were retrospectively reviewed. Results. There were 34 subjects included in the analysis. Baseline CNV sizes of less than 1.0 mm(2) on ICG angiography correlated with complete CNV resolution (P = 0.0404), fewer injections delivered (P = 0.0002), and better Snellen visual acuity (P = 0.0098) at 12 months. Subjects that experienced a 33% or more reduction in CNV size on ICG angiography at 2 months had complete CNV resolution (P = 0.0047) and fewer injections (P < 0.0001) at 12 months compared to subjects that did not experience a 33% or more reduction in CNV size on ICG angiography at 2 months. Conclusions. Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy.

No MeSH data available.


Related in: MedlinePlus